Climb Bio rises after early-stage data for kidney disease drug
BUZZ-Climb Bio rises after early-stage data for kidney disease drug ** Shares of drug developer Climb Bio CLYM.O rise 6.3% to $16 premarket
** Co says its experimental kidney disease drug, CLYM116, showed durable activity and a favorable safety profile in an early-stage trial
** The data came from an ongoing early-stage study in 46 healthy volunteers testing CLYM116, an anti-APRIL antibody being developed for IgA nephropathy
** Co says a single 320-milligram dose reduced levels of the APRIL, a protein that helps drive production of antibodies, by more than 90% and lowered disease-related antibodies by about 60% to 75% for up to 12 weeks
** Says the drug had a projected half-life of about 29 days, which could support less frequent dosing; this is threefold longer than Otsuka's 4578.T sibeprenlimab
** Oppenheimer says, "The Ph1 healthy volunteer PK/PD data give clear support to every 12-week dosing, putting CLYM on solid competitive footing in our view"
** Co expects initial mid-stage data in the first half of 2027
** As of last close, stock has more than tripled YTD
(Reporting by Siddhi Mahatole)